Roles of Rheb(S16H) in substantia nigra pars compacta dopaminergic neurons in vivo

Biomedical Reports
Min-Tae Jeon, Sang Ryong Kim

Abstract

Although there are ongoing intensive research efforts, no effective pharmacological therapies for Parkinson's disease (PD) have been developed thus far. However, with the development of efficient gene delivery systems, gene therapy for PD has become a focus of research and increasing evidence suggests that continuous production of neurotrophic factors play a significant role in the functional restoration of the nigrostriatal dopaminergic (DA) system. Our recent study reported that the transduction of DA neurons with ras homolog enriched in brain, which has an S16H mutation [Rheb(S16H)], protected the nigrostriatal DA projection in a neurotoxin model of PD in vivo. In addition, Rheb(S16H) expression significantly increased the levels of glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor, which contributed to the neuroprotective effects of Rheb(S16H) in DA neurons in the adult brain, indicating that the activation of the signaling pathways involved in cell survival by a specific gene delivery, such as Rheb(S16H) to adult neurons, may be a useful strategy to protect neural systems in the adult brain. In the present study, a brief overview of our recent studies is provided, which demonstrates the neur...Continue Reading

References

Mar 1, 1997·The European Journal of Neuroscience·N A PochonP Aebischer
Jun 24, 1997·Proceedings of the National Academy of Sciences of the United States of America·D J CreedonE M Johnson
Dec 2, 1999·Genes & Development·S R DattaM E Greenberg
Sep 30, 2000·Brain Research. Brain Research Reviews·G J Siegel, N B Chauhan
Oct 14, 2000·Experimental Neurology·D W HowellsG A Donnan
Jan 15, 2003·Neurology·J G NuttUNKNOWN ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor
Jul 11, 2006·The Journal of Clinical Investigation·Joseph M SavittTed M Dawson
Oct 26, 2007·Trends in Neurosciences·Ning ChangQi Wan
Apr 9, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Amie L Peterson, John G Nutt
Jun 10, 2008·Nature Neuroscience·Alberto PascualJosé López-Barneo
Aug 6, 2010·The Journal of Biological Chemistry·Sascha KarassekRaphael Stoll
Dec 15, 2010·Trends in Neurosciences·Liviu Aron, Rüdiger Klein
Mar 26, 2011·Annals of Neurology·Sang Ryong KimRobert E Burke
Oct 20, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sang Ryong KimRobert E Burke
Jan 31, 2012·Experimental Neurology·Robert E Burke, Karen O'Malley
Apr 5, 2012·Cold Spring Harbor Perspectives in Medicine·Philippe G CounePatrick Aebischer
Jan 26, 2013·Pharmacology & Therapeutics·Shelley J AllenNikunj K Patel
Dec 21, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Raymond T BartusR Jude Samulski
Jun 26, 2014·Experimental Neurobiology·Un Ju JungSang Ryong Kim

❮ Previous
Next ❯

Citations

Feb 18, 2017·Biological Chemistry·Veena Nambiar PotheraveeduRolf Heumann
Mar 20, 2020·International Journal of Molecular Sciences·Gyeong Joon MoonSang Ryong Kim
Apr 4, 2021·International Journal of Molecular Sciences·Youngpyo NamSang Ryong Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.